This is Why Investors are Buzzing Over a Potential $2 Billion CBD Beverage Market March 03, 2022 - Baystreet.ca The global cannabis beverage market could see strong growth. In fact, as noted by JD Supra, “With industry experts claiming that the ‘best way to consume cannabinoids is through a beverage,’ and Nasdaq reporting on the investment opportunities that surround CBD beverages, it is no surprise that CBD beverages are exploding in popularity.” Fueling further upside, global Industry Analysts says the market could be worth $2 billion by 2026. All of which could create massive opportunity for Xebra Brands (CSE:XBRA)(OTCQB:XBRAF), Aurora Cannabis (NASDAQ:ACB)(TSX:ACB), Canopy Growth (TSX:WEED) (NASDAQ:CGC), Tilray Inc. (NASDAQ:TLRY)(TSX:TLRY), and OrganiGram Holdings (NASDAQ:OGI)(TSX:OGI). In addition, according to Grand View Research, the market could be worth $2.8 billion by 2025. “The rising popularity of wellness drinks is also expected to support the demand over the forecast period. The legalization of cannabis for medical and recreational purposes has had a strong impact on the sales of alcoholic drinks. As a result, many alcohol manufacturers are investing in the growing trend of marijuana-infused drinks,” they noted. Xebra Brands’ (CSE:XBRA)(OTCQB:XBRAF) Readies for Launch of its Unique and Pioneering Cannabis Infused Lemonade in Canada Xebra Brands Ltd. a cannabis company, is pleased to report on its progress towards having its first cannabis beverage product, Vicious Citrus Lemonade available for sale in Canada. The Xebra team has been actively targeting the three major provinces of Alberta, British Columbia and Ontario with its differentiated product offering. Vicious Citrus Lemonade, combines 10mg of THC with 2mg of CBN (Cannabinol) per serving for an entourage experience that cannot be found in most cannabis products in Canada. To Xebra’s knowledge, Vicious Citrus is one of only very few beverages in Canada containing CBN. CBN is a unique cannabinoid that is booming in interest across North America. Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have growing excitement about for its adult use effects and potential medicinal benefits. In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone human testing. The human testing was carried-out with the approval of Health Canada. “The response from the provinces and dispensaries has been very positive. We have selected our co-packer and look forward to starting production in the spring with the target of being on shelves for summer 2022“, said Rodrigo Gallardo, President of Xebra. Xebra has engaged Route 1, a cannabis sales & marketing agency to introduce Vicious Citrus Lemonade to Canadian dispensaries. Chris Hart, Founder and CEO of Route 1, stated, “Route 1 is excited to represent Xebra and is looking forward to focusing on marketing and promoting their pioneering product containing CBN. Xebra has created a product that not only tastes great, but is differentiated in various ways that I feel will resonate well with the end customer.” Other related developments from around the markets include: Aurora Cannabis, the Canadian company defining the future of cannabinoids worldwide, announced its financial and operational results for the second quarter fiscal 2022 ended December 31, 2021. "During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Our focus remains on further cost reductions, and we are pleased to announce today that we expect to reach the high end of the $60 to $80 million range. Our balance sheet remains among the strongest in the industry, with approximately $445 million in cash as of yesterday. This gives us significant working capital to support organic growth and positions us to pursue strategic M&A opportunities," stated Miguel Martin, Chief Executive Officer of Aurora. Canopy Growth announced its financial results for the third quarter fiscal 2022 ended December 31, 2021. “In the third quarter we actioned to win where it matters – driving record performance in our CPG business from both BioSteel and Storz & Bickel, while beginning to stabilize our Canadian business including maintaining the #1 position in premium flower. Our continued discipline and focus are expected to fortify Canopy’s competitive positioning in Canada as we ambitiously build our U.S. CPG, CBD, and THC strategies,” said David Klein, CEO. Tilray Inc., a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced that its medical cannabis division, Tilray Medical, has completed its first sale of medical cannabis in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis. Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “As demand for cannabis continues to grow across Europe, we’re incredibly proud to partner with established and reliable distribution partners to supply new markets with high-quality medical cannabis which patients can rely on.” OrganiGram Holdings announced its results for the first quarter ended November 30, 2021. “Our record-breaking results in the first quarter of Fiscal 2022 are a testament to our successful strategy to create innovative, high-quality products that align with the evolving preferences of the various segments of cannabis consumers,” said Beena Goldenberg. “Our positive outlook for 2022 is further bolstered by the addition of Laurentian’s premium products to our portfolio, with an increased presence in Quebec and the resumption of international sales, which will continue through the year.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Xebra Brands has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Xebra Brands. Click here for disclaimer. Contact Information: 2818047972 [email protected]
This is Why Investors are Buzzing Over a Potential $2 Billion CBD Beverage Market March 03, 2022 - Baystreet.ca The global cannabis beverage market could see strong growth. In fact, as noted by JD Supra, “With industry experts claiming that the ‘best way to consume cannabinoids is through a beverage,’ and Nasdaq reporting on the investment opportunities that surround CBD beverages, it is no surprise that CBD beverages are exploding in popularity.” Fueling further upside, global Industry Analysts says the market could be worth $2 billion by 2026. All of which could create massive opportunity for Xebra Brands (CSE:XBRA)(OTCQB:XBRAF), Aurora Cannabis (NASDAQ:ACB)(TSX:ACB), Canopy Growth (TSX:WEED) (NASDAQ:CGC), Tilray Inc. (NASDAQ:TLRY)(TSX:TLRY), and OrganiGram Holdings (NASDAQ:OGI)(TSX:OGI). In addition, according to Grand View Research, the market could be worth $2.8 billion by 2025. “The rising popularity of wellness drinks is also expected to support the demand over the forecast period. The legalization of cannabis for medical and recreational purposes has had a strong impact on the sales of alcoholic drinks. As a result, many alcohol manufacturers are investing in the growing trend of marijuana-infused drinks,” they noted. Xebra Brands’ (CSE:XBRA)(OTCQB:XBRAF) Readies for Launch of its Unique and Pioneering Cannabis Infused Lemonade in Canada Xebra Brands Ltd. a cannabis company, is pleased to report on its progress towards having its first cannabis beverage product, Vicious Citrus Lemonade available for sale in Canada. The Xebra team has been actively targeting the three major provinces of Alberta, British Columbia and Ontario with its differentiated product offering. Vicious Citrus Lemonade, combines 10mg of THC with 2mg of CBN (Cannabinol) per serving for an entourage experience that cannot be found in most cannabis products in Canada. To Xebra’s knowledge, Vicious Citrus is one of only very few beverages in Canada containing CBN. CBN is a unique cannabinoid that is booming in interest across North America. Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have growing excitement about for its adult use effects and potential medicinal benefits. In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone human testing. The human testing was carried-out with the approval of Health Canada. “The response from the provinces and dispensaries has been very positive. We have selected our co-packer and look forward to starting production in the spring with the target of being on shelves for summer 2022“, said Rodrigo Gallardo, President of Xebra. Xebra has engaged Route 1, a cannabis sales & marketing agency to introduce Vicious Citrus Lemonade to Canadian dispensaries. Chris Hart, Founder and CEO of Route 1, stated, “Route 1 is excited to represent Xebra and is looking forward to focusing on marketing and promoting their pioneering product containing CBN. Xebra has created a product that not only tastes great, but is differentiated in various ways that I feel will resonate well with the end customer.” Other related developments from around the markets include: Aurora Cannabis, the Canadian company defining the future of cannabinoids worldwide, announced its financial and operational results for the second quarter fiscal 2022 ended December 31, 2021. "During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Our focus remains on further cost reductions, and we are pleased to announce today that we expect to reach the high end of the $60 to $80 million range. Our balance sheet remains among the strongest in the industry, with approximately $445 million in cash as of yesterday. This gives us significant working capital to support organic growth and positions us to pursue strategic M&A opportunities," stated Miguel Martin, Chief Executive Officer of Aurora. Canopy Growth announced its financial results for the third quarter fiscal 2022 ended December 31, 2021. “In the third quarter we actioned to win where it matters – driving record performance in our CPG business from both BioSteel and Storz & Bickel, while beginning to stabilize our Canadian business including maintaining the #1 position in premium flower. Our continued discipline and focus are expected to fortify Canopy’s competitive positioning in Canada as we ambitiously build our U.S. CPG, CBD, and THC strategies,” said David Klein, CEO. Tilray Inc., a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced that its medical cannabis division, Tilray Medical, has completed its first sale of medical cannabis in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis. Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “As demand for cannabis continues to grow across Europe, we’re incredibly proud to partner with established and reliable distribution partners to supply new markets with high-quality medical cannabis which patients can rely on.” OrganiGram Holdings announced its results for the first quarter ended November 30, 2021. “Our record-breaking results in the first quarter of Fiscal 2022 are a testament to our successful strategy to create innovative, high-quality products that align with the evolving preferences of the various segments of cannabis consumers,” said Beena Goldenberg. “Our positive outlook for 2022 is further bolstered by the addition of Laurentian’s premium products to our portfolio, with an increased presence in Quebec and the resumption of international sales, which will continue through the year.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Xebra Brands has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Xebra Brands. Click here for disclaimer. Contact Information: 2818047972 [email protected]